Status:
COMPLETED
Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
Lead Sponsor:
Ohio State University
Conditions:
Preeclampsia With Severe Features
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This is a single site pilot randomized, controlled, trial randomizing patients with PE with severe features to one of 2 groups: * 24 hours of postpartum magnesium sulfate (current arbitrary standard ...
Eligibility Criteria
Inclusion
- Preeclampsia with severe features, diagnosed using the American Congress of Obstetricians and Gynecologists (ACOG) standard criteria 4 requiring magnesium sulfate
- Females older than 18 years of age
- Singleton pregnancy
- Gestational age greater than 24 0/7 weeks
- The patient is physically and mentally able to understand the informed consent and is willing to participate in this study
- Able to speak English or Spanish
Exclusion
- Multiple gestation
- Prisoners
- Patients with chronic renal insufficiency or epilepsy
- Known cardiovascular disease
- Patients with contraindications to magnesium sulfate use (e.g. myasthenia gravis)
- Patients with eclampsia or HELLP syndrome
- Contraindications for magnesium sulfate
Key Trial Info
Start Date :
February 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04474704
Start Date
February 22 2021
End Date
May 31 2022
Last Update
June 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Columbus, Ohio, United States, 43210